You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTetracycline
Accession NumberDB00759  (APRD00572)
TypeSmall Molecule
GroupsApproved
Description

Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells.

Structure
Thumb
Synonyms
(4S,4AS,5as,12as)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide
Abramycin
Achromycin
Anhydrotetracycline
Deschlorobiomycin
Liquamycin
Tetracyclin
Tétracycline
Tetracyclinum
Tetrazyklin
Tsiklomitsin
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Achromycin Ont Oph 1%ointment1 %ophthalmicLederle Cyanamid Canada Inc.1955-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Achromycin Vcapsule500 mg/1oralHeritage Pharmaceuticals Inc.2013-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Achromycin Vcapsule250 mg/1oralHeritage Pharmaceuticals Inc.2013-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Achromycin V Cap 250mgcapsule250 mgoralLederle Cyanamid Canada Inc.1957-12-311997-08-14Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Actisitemiscellaneous12.7 mgdentalProcter & Gamble IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Jaa Tetra Tab 250mgtablet250 mgoralJaapharm Canada Inc.1993-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Medicycline Cap 250mgcapsule250 mgoralMedic Laboratory LtÉe1962-12-311996-09-09Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-tetra 250mgcapsule250 mgoralNovopharm Limited1967-12-312008-08-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-tetra 250mgtablet250 mgoralNovopharm Limited1967-12-312008-08-20Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Novo-tetra Sus 125mg/5mlliquid125 mgoralNovopharm Limited1967-12-312005-08-10Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-tetra Capsules 250mgcapsule250 mgoralNu Pharm Inc1990-12-312012-09-04Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tetracyclinecapsule250 mgoralAa Pharma Inc1983-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tetracycline 1% Onguent Ophthalmicointment10 mgophthalmicLaboratoires Sterigen Inc1988-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tetracycline Cap 250mgcapsule250 mgoralDuchesnay Inc1981-12-312003-07-18Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tetracycline Cap 250mgcapsule250 mgoralPro Doc Limitee1962-12-312012-07-23Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tetracycline Hydrochloridecapsule250 mg/1oralHeritage Pharmaceuticals Inc.2013-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralHeritage Pharmaceuticals Inc.2013-10-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracyn Cap 250mgcapsule250 mgoralPfizer Canada Inc1952-12-312000-07-26Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Tetra Tabs 250mgtablet250 mgoralApotex Inc1984-12-312008-08-21Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Tetracycline Hydrochloridecapsule250 mg/1oralLiberty Pharmaceuticals, Inc.2000-01-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralChartwell Rx, Llc2015-12-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralRebel Distributors Corp2010-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralbryant ranch prepack2010-12-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralRebel Distributors Corp2010-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralbryant ranch prepack2010-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralSTAT Rx USA LLC2010-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralPhysicians Total Care, Inc.1996-10-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralSTAT Rx USA LLC2010-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralPhysicians Total Care, Inc.1988-03-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralBlenheim Pharmacal, Inc.2010-03-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralWatson Laboratories, Inc.2011-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralH.J. Harkins Company, Inc.2010-03-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralREMEDYREPACK INC.2011-12-132015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralWatson Laboratories, Inc.2011-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralChartwell Rx, Llc2015-12-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule250 mg/1oralREMEDYREPACK INC.2011-05-16Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline Hydrochloridecapsule500 mg/1oralContract Pharmacy Services Pa2010-03-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acnecyclineointment.03 mg/mLtopicalPhillips Company2011-02-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Diabeclineointment30 mg/mLtopicalThru Pharma, Llc2013-05-23Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Diabeclineointment30 mg/gtopicalPhillips Company2013-06-10Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Dyabetexointment.03 mg/mLtopicalPhillips Company2010-08-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetra-abcointment.03 mg/mLtopicalPhillips Company2010-08-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetracycline-abcointment.03 mg/mLtopicalPhillips Company2011-02-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetrastemointment30 mg/gtopicalViaderma Ii, Inc.2014-05-282015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Tetrastemointment30 mg/gtopicalPhillips Company2014-02-25Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
International Brands
NameCompany
AchromycinNot Available
Brand mixtures
NameLabellerIngredients
First Marys Mouthwash CompoundingCutis Pharma, Inc.
PyleraPhysicians Total Care, Inc.
Salts
Name/CASStructureProperties
Tetracycline hydrochloride
64-75-5
Thumb
  • InChI Key: YCIHPQHVWDULOY-FMZCEJRJSA-N
  • Monoisotopic Mass: 480.129943493
  • Average Mass: 480.896
DBSALT000361
Tetracycline phosphate
ThumbNot applicableDBSALT001631
Categories
CAS number60-54-8
WeightAverage: 444.4346
Monoisotopic: 444.153265754
Chemical FormulaC22H24N2O8
InChI KeyInChIKey=OFVLGDICTFRJMM-WESIUVDSSA-N
InChI
InChI=1S/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1
IUPAC Name
(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][C@@]12C[C@@]3([H])C(=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@H]2N(C)C)C(=O)C1=C(O)C=CC=C1[C@@]3(C)O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassTetracyclines
Sub ClassNot Available
Direct ParentTetracyclines
Alternative Parents
Substituents
  • Tetracycline
  • Tetracene
  • Naphthacene
  • Anthracene carboxylic acid or derivatives
  • Tetralin
  • Aryl ketone
  • Aralkylamine
  • Benzenoid
  • Vinylogous acid
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Primary carboxylic acid amide
  • Polyol
  • Ketone
  • Carboxamide group
  • Enol
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin.
PharmacodynamicsTetracycline is a short-acting antibiotic that inhibits bacterial growth by inhibiting translation. It binds to the 30S ribosomal subunit and prevents the amino-acyl tRNA from binding to the A site of the ribosome. It also binds to some extent to the 50S ribosomal subunit. This binding is reversible in nature. Additionally tetracycline may alter the cytoplasmic membrane of bacteria causing leakage of intracellular contents, such as nucleotides, from the cell.
Mechanism of actionTetracycline passively diffuses through porin channels in the bacterial membrane and reversibly binds to the 30S ribosomal subunit, preventing binding of tRNA to the mRNA-ribosome complex, and thus interfering with protein synthesis.
AbsorptionBioavailability is less than 40% when administered via intramuscular injection, 100% intravenously, and 60-80% orally (fasting adults). Food and/or milk reduce GI absorption of oral preparations of tetracycline by 50% or more.
Volume of distributionNot Available
Protein binding20 - 67% protein bound
Metabolism

Not metabolized

Route of eliminationThey are concentrated by the liver in the bile and excreted in the urine and feces at high concentrations in a biologically active form.
Half life6-12 hours
ClearanceNot Available
ToxicityLD50=808mg/kg (orally in mice)
Affected organisms
  • Enteric bacteria and other eubacteria
  • Borrelia burgdorferi
  • Chlamydia trachomatis
  • Mycoplasma pneumoniae
  • Rickettsia rickettsii
  • Vibrio cholerae
  • Escherichia coli
  • Shigella
  • Coxiella
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8006
Blood Brain Barrier-0.9841
Caco-2 permeable+0.7439
P-glycoprotein substrateSubstrate0.791
P-glycoprotein inhibitor INon-inhibitor0.8025
P-glycoprotein inhibitor IINon-inhibitor0.7562
Renal organic cation transporterNon-inhibitor0.9437
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.6758
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9089
CYP450 3A4 inhibitorNon-inhibitor0.8686
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.781
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9314
BiodegradationNot ready biodegradable0.9906
Rat acute toxicity2.7095 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9968
hERG inhibition (predictor II)Non-inhibitor0.7201
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Heritage pharmaceuticals inc
  • Bristol laboratories inc div bristol myers co
  • Warner chilcott div warner lambert co
  • Pharmacia and upjohn co
  • Solvay pharmaceuticals
  • Wyeth ayerst laboratories
  • Apothecon inc div bristol myers squibb
  • Angus chemical co
  • Pfipharmecs div pfizer inc
  • On site therapeutics inc
  • Shire development inc
  • Lederle laboratories div american cyanamid co
  • Pfizer laboratories div pfizer inc
  • Storz ophthalmics inc sub american cyanamid co
  • Par pharmaceutical
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
Packagers
Dosage forms
FormRouteStrength
Ointmentophthalmic1 %
Miscellaneousdental12.7 mg
Ointmenttopical30 mg/mL
Ointmenttopical30 mg/g
Kitoral
Tabletoral250 mg
Liquidoral125 mg
Capsuleoral
Ointmenttopical.03 mg/mL
Capsuleoral250 mg
Ointmentophthalmic10 mg
Capsuleoral250 mg/1
Capsuleoral500 mg/1
Prices
Unit descriptionCostUnit
Tetracycline hcl powder2.14USD g
Tetracycline powder1.37USD g
Tetracycline HCl 500 mg capsule0.2USD capsule
Tetracycline HCl 250 mg capsule0.15USD capsule
Apo-Tetra 250 mg Capsule0.07USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point172.5 dec °CPhysProp
water solubility231 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-1.30HANSCH,C ET AL. (1995)
logS-3.12ADME Research, USCD
pKa3.3 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility1.33 mg/mLALOGPS
logP-0.56ALOGPS
logP-3.5ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)-2.2ChemAxon
pKa (Strongest Basic)8.24ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area181.62 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity114.19 m3·mol-1ChemAxon
Polarizability43.03 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Thomas F. McNamara, Nungavaram S. Ramamurthy, Lorne M. Golub, “Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same.” U.S. Patent US4704383, issued May, 1963.

US4704383
General References
  1. Link
  2. Griffin MO, Fricovsky E, Ceballos G, Villarreal F: Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48. Epub 2010 Jun 30. Pubmed
External Links
ATC CodesA01AB13D06AA04J01AA07S01AA09S02AA08S03AA02
AHFS Codes
  • 08:12.24
  • 52:04.04
PDB Entries
FDA labelNot Available
MSDSDownload (73.8 KB)
Interactions
Drug Interactions
Drug
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmdinocillinThe therapeutic efficacy of Amdinocillin can be decreased when used in combination with Tetracycline.
AmoxicillinThe therapeutic efficacy of Amoxicillin can be decreased when used in combination with Tetracycline.
AmpicillinThe therapeutic efficacy of Ampicillin can be decreased when used in combination with Tetracycline.
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Tetracycline.
AzidocillinThe therapeutic efficacy of Azidocillin can be decreased when used in combination with Tetracycline.
AzlocillinThe therapeutic efficacy of Azlocillin can be decreased when used in combination with Tetracycline.
BacampicillinThe therapeutic efficacy of Bacampicillin can be decreased when used in combination with Tetracycline.
BenzylpenicillinThe therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Tetracycline.
BexaroteneThe serum concentration of Tetracycline can be decreased when it is combined with Bexarotene.
Bismuth SubcitrateThe serum concentration of Tetracycline can be decreased when it is combined with Bismuth Subcitrate.
Bismuth SubsalicylateThe serum concentration of Tetracycline can be decreased when it is combined with Bismuth Subsalicylate.
BosentanThe serum concentration of Tetracycline can be decreased when it is combined with Bosentan.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbenicillinThe therapeutic efficacy of Carbenicillin can be decreased when used in combination with Tetracycline.
CloxacillinThe therapeutic efficacy of Cloxacillin can be decreased when used in combination with Tetracycline.
ColesevelamColesevelam can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclacillinThe therapeutic efficacy of Cyclacillin can be decreased when used in combination with Tetracycline.
DabrafenibThe serum concentration of Tetracycline can be decreased when it is combined with Dabrafenib.
DeferasiroxThe serum concentration of Tetracycline can be decreased when it is combined with Deferasirox.
DicloxacillinThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Tetracycline.
DicoumarolTetracycline may increase the anticoagulant activities of Dicoumarol.
FlucloxacillinThe therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Tetracycline.
HetacillinThe therapeutic efficacy of Hetacillin can be decreased when used in combination with Tetracycline.
Iron DextranTetracycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.
LanthanumThe serum concentration of Tetracycline can be decreased when it is combined with Lanthanum.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
MecamylamineTetracycline may increase the neuromuscular blocking activities of Mecamylamine.
MeticillinThe therapeutic efficacy of Meticillin can be decreased when used in combination with Tetracycline.
MezlocillinThe therapeutic efficacy of Mezlocillin can be decreased when used in combination with Tetracycline.
MipomersenTetracycline may increase the hepatotoxic activities of Mipomersen.
MitotaneThe serum concentration of Tetracycline can be decreased when it is combined with Mitotane.
NafcillinThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Tetracycline.
OxacillinThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Tetracycline.
PhenoxymethylpenicillinThe therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Tetracycline.
PhenytoinThe metabolism of Tetracycline can be increased when combined with Phenytoin.
PiperacillinThe therapeutic efficacy of Piperacillin can be decreased when used in combination with Tetracycline.
PivampicillinThe therapeutic efficacy of Pivampicillin can be decreased when used in combination with Tetracycline.
PivmecillinamThe therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Tetracycline.
PorfimerTetracycline may increase the photosensitizing activities of Porfimer.
QuinaprilThe serum concentration of Tetracycline can be decreased when it is combined with Quinapril.
QuinineThe serum concentration of Quinine can be increased when it is combined with Tetracycline.
SiltuximabThe serum concentration of Tetracycline can be decreased when it is combined with Siltuximab.
Sodium picosulfateThe therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Tetracycline.
St. John's WortThe serum concentration of Tetracycline can be decreased when it is combined with St. John's Wort.
Strontium ranelateThe serum concentration of Tetracycline can be decreased when it is combined with Strontium ranelate.
SucralfateSucralfate can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Sucroferric OxyhydroxideThe serum concentration of Tetracycline can be decreased when it is combined with Sucroferric Oxyhydroxide.
TicarcillinThe therapeutic efficacy of Ticarcillin can be decreased when used in combination with Tetracycline.
TocilizumabThe serum concentration of Tetracycline can be decreased when it is combined with Tocilizumab.
VerteporfinTetracycline may increase the photosensitizing activities of Verteporfin.
Food Interactions
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminium salts 2 hours before or 6 hours after using antacids while on this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.
  • Take with a full glass of water.

Targets

1. 30S ribosomal protein S7

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S7 P02359 Details

References:

  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. Pubmed

2. 30S ribosomal protein S14

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S14 P0AG59 Details

References:

  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. Pubmed

3. 30S ribosomal protein S3

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S3 P0A7V3 Details

References:

  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. Pubmed

4. 30S ribosomal protein S8

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S8 P0A7W7 Details

References:

  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. Pubmed

5. 30S ribosomal protein S19

Kind: Protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
30S ribosomal protein S19 P0A7U3 Details

References:

  1. Buck MA, Cooperman BS: Single protein omission reconstitution studies of tetracycline binding to the 30S subunit of Escherichia coli ribosomes. Biochemistry. 1990 Jun 5;29(22):5374-9. Pubmed

6. 16S rRNA

Kind: Nucleotide

Organism: Enteric bacteria and other eubacteria

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details

References:

  1. Nawaz M, Sung K, Khan SA, Khan AA, Steele R: Biochemical and molecular characterization of tetracycline-resistant Aeromonas veronii isolates from catfish. Appl Environ Microbiol. 2006 Oct;72(10):6461-6. Pubmed
  2. Domingue GJ Sr: Cryptic bacterial infection in chronic prostatitis: diagnostic and therapeutic implications. Curr Opin Urol. 1998 Jan;8(1):45-9. Pubmed
  3. Pringle M, Fellstrom C, Johansson KE: Decreased susceptibility to doxycycline associated with a 16S rRNA gene mutation in Brachyspira hyodysenteriae. Vet Microbiol. 2007 Jul 20;123(1-3):245-8. Epub 2007 Feb 25. Pubmed
  4. Rasmussen B, Noller HF, Daubresse G, Oliva B, Misulovin Z, Rothstein DM, Ellestad GA, Gluzman Y, Tally FP, Chopra I: Molecular basis of tetracycline action: identification of analogs whose primary target is not the bacterial ribosome. Antimicrob Agents Chemother. 1991 Nov;35(11):2306-11. Pubmed

7. Major prion protein

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Major prion protein P04156 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. De Luigi A, Colombo L, Diomede L, Capobianco R, Mangieri M, Miccolo C, Limido L, Forloni G, Tagliavini F, Salmona M: The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One. 2008 Mar 26;3(3):e1888. Pubmed

8. Multidrug translocase MdfA

Kind: Protein

Organism: Escherichia coli

Pharmacological action: unknown

Components

Name UniProt ID Details
Multidrug translocase MdfA C9EH48 Details

References:

  1. Nelson ML, Park BH, Andrews JS, Georgian VA, Thomas RC, Levy SB: Inhibition of the tetracycline efflux antiport protein by 13-thio-substituted 5-hydroxy-6-deoxytetracyclines. J Med Chem. 1993 Feb 5;36(3):370-7. Pubmed

9. Protein-arginine deiminase type-4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Protein-arginine deiminase type-4 Q9UM07 Details

References:

  1. Knuckley B, Luo Y, Thompson PR: Profiling Protein Arginine Deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg Med Chem. 2008 Jan 15;16(2):739-45. Epub 2007 Oct 13. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Carriers

1. Serum albumin

Kind: Protein

Organism: Human

Pharmacological action: no

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Bratlid D, Bergan T: Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology. 1976;14(5):464-72. Pubmed

Transporters

1. Solute carrier family 22 member 6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

2. Solute carrier family 22 member 8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 8 Q8TCC7 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

3. Solute carrier family 22 member 11

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 11 Q9NSA0 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

4. Solute carrier family 22 member 7

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 7 Q9Y694 Details

References:

  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 04, 2016 12:01